Log in or create an account to engage on OVdialogue.
Like many of you, I am deeply disappointed by this news and recognize how difficult it will be for many in our community to hear. We know so many have been following the progress of ELAHERE closely and had hoped this treatment would become accessible to Canadians living with ovarian cancer.
While there are still many unanswered questions and the situation continues to evolve, please know that Ovarian Cancer Canada remains actively engaged and committed to advocating for timely access to new treatment options for our community.
Below is Ovarian Cancer Canada's full statement regarding the conclusion of ELAHERE negotiations in Canada.
We are deeply disappointed by this outcome and stand with patients with ovarian cancer as they face the loss of access to a critically needed treatment option.
On May 14, 2026, the status of negotiations for ELAHERE (mirvetuximab soravtansine) between the pan-Canadian Pharmaceutical Alliance (pCPA) and AbbVie, the drug's manufacturer, was updated to concluded without agreement. The termination of the process means that Canadians undergoing ovarian cancer treatment will not be provided with access to ELAHERE through public drug programs. After years of advocacy by Ovarian Cancer Canada and our community, and decades without new treatments to improve survival outcomes, this result is a devastating and unacceptable outcome. Canadians must have access to life-extending targeted treatments as quickly as possible.
"Health Canada's approval of ELAHERE in 2025 offered women diagnosed with ovarian cancer hope of a new treatment that could extend their lifespan. The end of ELAHERE negotiations has damaged that hope," stated Tania Vrionis, CEO of Ovarian Cancer Canada. "After decades without a new ovarian cancer treatment, having ELAHERE available and accessible to Canadians would have been a critically needed update to their care. It is unacceptable for a new treatment to be available and withhold it from those who need it most. We're encouraging all stakeholders to return to the table and restart negotiations to make ELAHERE available to Canadians."
We will continue to advocate for innovative treatments to be available in Canada as quickly as possible.
After generations of women being overlooked, the Health Canada approval of ELAHERE and positive reimbursement recommendation from Canada's Drug Agency in Fall 2025 was meaningful progress to transform the lives of those diagnosed with ovarian cancer. That progress was fragile and today's decision to end the discussions has fundamentally damaged it.
We will continue to monitor and report on the process to make ELAHERE available to Canadians.